Boston Scientific Corp. (BSX)

43.29
NYSE : Health Technology
Prev Close 43.06
Day Low/High 42.85 / 43.40
52 Wk Low/High 31.56 / 43.84
Avg Volume 5.50M
Exchange NYSE
Shares Outstanding 1.39B
Market Cap 59.98B
EPS 1.20
P/E Ratio 42.75
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Corp. Takes Over #99 Spot From ConocoPhillips

Boston Scientific Corp. Takes Over #99 Spot From ConocoPhillips

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Boston Scientific Corp. has taken over the #99 spot from ConocoPhillips , according to The Online Investor.

Boston Scientific Closes Acquisition Of BTG Plc.

Boston Scientific Closes Acquisition Of BTG Plc.

MARLBOROUGH, Mass., Aug.

Boston Scientific To Participate In 39th Annual Canaccord Genuity Growth Conference

Boston Scientific To Participate In 39th Annual Canaccord Genuity Growth Conference

MARLBOROUGH, Mass., July 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 39 th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston.

Boston Scientific Announces Results For Second Quarter 2019

Boston Scientific Announces Results For Second Quarter 2019

MARLBOROUGH, Mass., July 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.

Boston Scientific Expected to Earn 38 Cents a Share

Boston Scientific Expected to Earn 38 Cents a Share

Boston Scientific revenue expected to rise 6.1% to $2.6 billion.

Boston Scientific Takes Over #11 Spot From Amazon.com

Boston Scientific Takes Over #11 Spot From Amazon.com

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Boston Scientific Corp. has taken over the #11 spot from Amazon.

Coming Up Short? Here Are Some Stocks to Consider

Coming Up Short? Here Are Some Stocks to Consider

To effectively generate profits, a trader must pick several companies in a sector and short the whole bunch.

Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results

Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results

MARLBOROUGH, Mass., July 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2019 on Wednesday, July 24, 2019 at 8:00...

Saluda Medical Raises $75 Million Equity Financing From Boston Scientific And Redmile Group

Saluda Medical Raises $75 Million Equity Financing From Boston Scientific And Redmile Group

ARTARMON, Australia, June 28, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that it has secured $75 million in equity financing from Boston Scientific Corporation (NYSE: BSX) and Redmile Group LLC to fund the final...

Boston Scientific Presents Strategies For Sustained Long-Range Growth Targets At 2019 Investor Day

Boston Scientific Presents Strategies For Sustained Long-Range Growth Targets At 2019 Investor Day

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow

Boston Scientific Closes Acquisition Of Vertiflex, Inc.

Boston Scientific Closes Acquisition Of Vertiflex, Inc.

MARLBOROUGH, Mass., June 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc.

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses To Contact The Firm

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses To Contact The Firm

SAN DIEGO, June 1, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below.

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure To Direct Oral Anticoagulants For Stroke Risk Reduction Post-AFib Ablation

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure To Direct Oral Anticoagulants For Stroke Risk Reduction Post-AFib Ablation

Findings could expand number of patients who can receive alternative treatment to life-long use of blood thinners

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE:BSX) of the June 24, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Boston Scientific To Participate In Bernstein's 35th Annual Strategic Decisions Conference

Boston Scientific To Participate In Bernstein's 35th Annual Strategic Decisions Conference

MARLBOROUGH, Mass., May 15, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35 th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Boston Scientific Corporation Of Class Action Lawsuit And Upcoming Deadline - BSX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Boston Scientific Corporation Of Class Action Lawsuit And Upcoming Deadline - BSX

NEW YORK, May 14, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE:  BSX) and certain of its officers.

Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific EMBLEM™ S-ICD System

Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific EMBLEM™ S-ICD System

New data further support use of S-ICD System as first-line therapy for majority of ICD patients

Boston Scientific Announces Agreement To Acquire Vertiflex, Inc.

Boston Scientific Announces Agreement To Acquire Vertiflex, Inc.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies

Boston Scientific To Participate In The 2019 UBS Global Healthcare Conference

Boston Scientific To Participate In The 2019 UBS Global Healthcare Conference

MARLBOROUGH, Mass., May 7, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City.

Boston Scientific Receives U.S. FDA Approval For The VICI VENOUS STENT™ System

Boston Scientific Receives U.S. FDA Approval For The VICI VENOUS STENT™ System

New Stent System Now Available for Treating Patients with Deep Venous Blockages

Boston Scientific Announces Scheduled Presentations At Heart Rhythm 2019

Boston Scientific Announces Scheduled Presentations At Heart Rhythm 2019

MARLBOROUGH, Mass., May 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May...

Boston Scientific To Participate In Bank Of America Merrill Lynch Healthcare Conference 2019

Boston Scientific To Participate In Bank Of America Merrill Lynch Healthcare Conference 2019

MARLBOROUGH, Mass., May 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE:BSX) of the June 24, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Boston Scientific Corp. Shareholder Alert: Securities Lawsuit Filed Against BSX

Boston Scientific Corp. Shareholder Alert: Securities Lawsuit Filed Against BSX

BOSTON, April 26, 2019 /PRNewswire/ -- Thornton Law Firm LLP announces that it is investigating a securities class action on behalf of shareholders and investors who purchased the securities of Boston Scientific Corporation (NYSE ticker: BSX).

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Boston Scientific Corporation To Contact The Firm

NEW YORK, April 25, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE:BSX) of the June 24, 2019 deadline to seek the role of...

Johnson Fistel Announces Class Action Suit Against Boston Scientific Corporation (BSX); Encourages Investors To Contact The Firm For Additional Information

Johnson Fistel Announces Class Action Suit Against Boston Scientific Corporation (BSX); Encourages Investors To Contact The Firm For Additional Information

SAN DIEGO, April 25, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") on behalf of all purchasers of...

TheStreet Quant Rating: B (Buy)